BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects
A Randomized, Blinded, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Adult Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands
- Research Site
-
-
-
-
California
-
Glendale, California, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be in good health
- BMI of 18-30kg/m2
- Contraception required for at least 6 months after study drug administration
Exclusion Criteria:
- History of clinically significant disease or lab values
- Females of childbearing potentials
- Contraindication to brain MRI and/or lumbar puncture
- Treatment with any prescription medication within the 28 days prior to study entry
- Treatment with any over-the-counter products, including herbal and/or alternative health preparations and procedures within the 14 days prior to study entry
- Regular use of any tobacco product within 3 months prior to study entry
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Single dose of saline solution (8 cohorts IV; 1 cohort SC)
|
Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
|
|
Experimental: BIIB033
Single, escalating doses of BIIB033 (8 cohorts IV; 1 cohort SC)
|
Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety as measured by adverse event monitoring, laboratory assessments and MRI
Time Frame: up to 4 months
|
up to 4 months
|
|
Tolerability as measured by adverse event monitoring, laboratory assessments and MRI
Time Frame: up to 4 months
|
up to 4 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
BIIB033 serum pharmacokinetics levels
Time Frame: up to 4 months
|
up to 4 months
|
|
BIIB033 serum antibodies levels
Time Frame: up to 4 months
|
up to 4 months
|
|
Exploratory blood, urine and CSF biomarkers
Time Frame: up to 4 months
|
up to 4 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 215HV101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.